This humanized anti-NogoA antibody was first used in 2014 by Meininger et al. for a phase I study in sporadic ALS patients where safety, pharmacokinetics (PK), and functional effects of Ozanezumab were assessed (Meininger et al., 2014). The gene discussed is RTN4; the disease is amyotrophic lateral sclerosis.